Siemens Healthineers has announced it is helping to shorten the time doctors can diagnose a life-threatening myocardial infarction with the introduction of two assays that—a press release claims—offer unparalleled precision. US FDA cleared High-Sensitivity Troponin I assays (TnIH)1 for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analysers from Siemens Healthineers to aid in the early diagnosis of myocardial infarctions.
The press release reports that the high-sensitivity performance of the two new Siemens Healthineers TnIH assays offers the ability to detect lower levels of troponin at significantly improved precision at the 99th percentile, and detect smaller changes in a patient’s troponin level as repeat testing occurs. This design affords clinicians greater confidence in the results with precision that provides the ability to measure slight, yet critical, changes to begin treatment. As science progresses, guidelines for determining high-sensitivity also evolves. These TnIH assays meet the latest industry guidelines.
Alan Wu (Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, USA), comments: “Our emergency department is overcrowded with patients. If we can do a more efficient job at triaging patients to receive the proper level of care and to discharge the patients who do not need to stay in the emergency department, this will have a tremendous economic advantage for our healthcare system.”